Period:
Draw Mode:
| Volume | 90,414 |
|
|||||
| News | - | ||||||
| Day High | 4.94 | Low High |
|||||
| Day Low | 4.35 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| MIRA Pharmaceuticals Inc | MIRA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.30 | 6.9% | 4.65 | 16:00:03 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.35 | 4.35 | 4.94 | 4.65 | 4.35 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 951 | 90,414 | $ 4.72 | $ 426,933 | - | 3.00 - 7.9799 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:00 | 20 | $ 4.65 | USD |
MIRA Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 68.73M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
MIRA Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MIRA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.18 | 5.30 | 3.92 | 4.37 | 67,783 | 0.47 | 11.24% |
| 1 Month | 6.42 | 6.77 | 3.00 | 4.47 | 199,495 | -1.77 | -27.57% |
| 3 Months | 7.00 | 7.9799 | 3.00 | 5.22 | 147,246 | -2.35 | -33.57% |
| 6 Months | 7.00 | 7.9799 | 3.00 | 5.22 | 147,246 | -2.35 | -33.57% |
| 1 Year | 7.00 | 7.9799 | 3.00 | 5.22 | 147,246 | -2.35 | -33.57% |
| 3 Years | 7.00 | 7.9799 | 3.00 | 5.22 | 147,246 | -2.35 | -33.57% |
| 5 Years | 7.00 | 7.9799 | 3.00 | 5.22 | 147,246 | -2.35 | -33.57% |
MIRA Pharmaceuticals Description
| MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland. |